Designing a more reasonable combination treatment plan based on the metabolic crosstalk between tumor and immune cells can avoid treatment failure and increase the effectiveness of PD-1/PD-L1 checkpoint blockade immunotherapy in more cancers. This evidence concerns the gene CD274 and cancer.